Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsJSE:APN +0.10%72 PS Ratio is 1.57 as of Jul. 19, 2026, which is 18% below its 10-year median of 1.92. GuruFocus rates JSE:APN with a GF Score™ of 72/100 and a GF Value™ of R170.84 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 954 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks better than 62.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aspen Pharmacare Holdings's share price is R150.32.
Aspen Pharmacare Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was R95.89. Hence, Aspen Pharmacare Holdings's PS Ratio for today is 1.57.
Warning Sign:
Aspen Pharmacare Holdings Ltd stock PS Ratio (=1.54) is close to 1-year high of 1.62.
The historical rank and industry rank for Aspen Pharmacare Holdings's PS Ratio or its related term are showing as below:
JSE:APN'
s PS Ratio Range Over the Past 10 Years
Min: 0.89 Med: 1.92 Max: 4.87
Current: 1.57
During the past 13 years, Aspen Pharmacare Holdings's highest PS Ratio was 4.87. The lowest was 0.89. And the median was 1.92.
JSE:APN's PS Ratio is ranked better than 62.89% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs JSE:APN: 1.57
Aspen Pharmacare Holdings Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Aspen Pharmacare Holdings was 2.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.00% per year.
During the past 13 years, Aspen Pharmacare Holdings's highest 3-Year average Revenue per Share Growth Rate was 33.40% per year. The lowest was -6.50% per year. And the median was 15.45% per year.
Back to Basics: PS Ratio
Aspen Pharmacare Holdings (JSE:APN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aspen Pharmacare Holdings PS Ratio Related Terms
Aspen Pharmacare Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aspen Pharmacare Holdings's Share Price of today is R150.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was R95.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aspen Pharmacare Holdings (JSE:APN) has a PS Ratio of 1.57 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aspen Pharmacare Holdings and its competitors. This is 18% below median its historical median of 1.92. Over the past decade, Aspen Pharmacare Holdings' PS Ratio has ranged from 0.89 to 4.87. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #354 out of 954 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Aspen Pharmacare Holdings' PS Ratio too high?
Aspen Pharmacare Holdings' current PS Ratio of 1.57 is 18% below median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 0.89 to a high of 4.87. The Drug Manufacturers industry median PS Ratio is 2.32. Aspen Pharmacare Holdings' value of 1.57 is 32.3% below this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #354 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aspen Pharmacare Holdings has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #354 out of 954 companies for PS Ratio. This puts Aspen Pharmacare Holdings in the upper half of its industry. The industry median PS Ratio is 2.32. Aspen Pharmacare Holdings' value of 1.57 is 32.3% below this benchmark. Historically, Aspen Pharmacare Holdings' own PS Ratio has ranged from 0.89 to 4.87 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 2.32, Aspen Pharmacare Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current PS Ratio of 1.57 is 32.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aspen Pharmacare Holdings and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current PS Ratio is 1.57, which is 18% below median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (JSE:APN) is currently considered Modestly Undervalued. The stock's GF Value™ is R170.84, compared to a current price of R150.32 — trading 12% below its estimated fair value. The current PS Ratio is 1.57, which is 18% below median its 10-year median of 1.92 and 32.3% below the Drug Manufacturers industry median of 2.32. Aspen Pharmacare Holdings' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aspen Pharmacare Holdings (JSE:APN), the current PS Ratio is 1.57 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (JSE:APN) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of R150.32 is trading 12% below its estimated GF Value™ of R170.84.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for JSE:APN:
PS Ratio: 1.57 (18% below median its 10-year median of 1.92)
GF Value™: R170.84 vs. price of R150.32 (12% below fair value)
Industry Position: 32.3% below the Drug Manufacturers median (#354 of 954)
No single metric tells the full story. See the JSE:APN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
72GF Score
Get the complete analysis for JSE:APN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:APN has been successfully added to your 
